These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 33057878)
1. PEGylated Lipid Polymeric Nanoparticle-Encapsulated Acyclovir for In Vitro Controlled Release and Ex Vivo Gut Sac Permeation. Mahmood S; Kiong KC; Tham CS; Chien TC; Hilles AR; Venugopal JR AAPS PharmSciTech; 2020 Oct; 21(7):285. PubMed ID: 33057878 [TBL] [Abstract][Full Text] [Related]
2. β-cyclodextrin chitosan-based hydrogels with tunable pH-responsive properties for controlled release of acyclovir: design, characterization, safety, and pharmacokinetic evaluation. Malik NS; Ahmad M; Alqahtani MS; Mahmood A; Barkat K; Khan MT; Tulain UR; Rashid A Drug Deliv; 2021 Dec; 28(1):1093-1108. PubMed ID: 34114907 [TBL] [Abstract][Full Text] [Related]
3. Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility. Vadlapudi AD; Cholkar K; Vadlapatla RK; Mitra AK J Ocul Pharmacol Ther; 2014 Feb; 30(1):49-58. PubMed ID: 24192229 [TBL] [Abstract][Full Text] [Related]
4. Development of a Novel Polymeric Nanocomposite Complex for Drugs with Low Bioavailability. Sithole MN; Choonara YE; du Toit LC; Kumar P; Marimuthu T; Kondiah PPD; Pillay V AAPS PharmSciTech; 2018 Jan; 19(1):303-314. PubMed ID: 28717975 [TBL] [Abstract][Full Text] [Related]
5. Enhancing Stability and Mucoadhesive Properties of Chitosan Nanoparticles by Surface Modification with Sodium Alginate and Polyethylene Glycol for Potential Oral Mucosa Vaccine Delivery. Amin MK; Boateng JS Mar Drugs; 2022 Feb; 20(3):. PubMed ID: 35323455 [No Abstract] [Full Text] [Related]
6. Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study. El-Gizawy SA; El-Maghraby GM; Hedaya AA Pharm Dev Technol; 2019 Dec; 24(10):1299-1307. PubMed ID: 31507245 [TBL] [Abstract][Full Text] [Related]
7. Nano and microparticulate chitosan-based systems for antiviral topical delivery. Calderón L; Harris R; Cordoba-Diaz M; Elorza M; Elorza B; Lenoir J; Adriaens E; Remon JP; Heras A; Cordoba-Diaz D Eur J Pharm Sci; 2013 Jan; 48(1-2):216-22. PubMed ID: 23159663 [TBL] [Abstract][Full Text] [Related]
8. Acyclovir Solid Lipid Nanoparticles for Skin Drug Delivery: Fabrication, Characterization and In vitro Study. Bhupinder K; Newton MJ Recent Pat Drug Deliv Formul; 2017; 11(2):132-146. PubMed ID: 28124592 [TBL] [Abstract][Full Text] [Related]
9. Polymeric micelles for acyclovir drug delivery. Sawdon AJ; Peng CA Colloids Surf B Biointerfaces; 2014 Oct; 122():738-745. PubMed ID: 25193154 [TBL] [Abstract][Full Text] [Related]
10. Development of Acyclovir-Loaded Albumin Nanoparticles and Improvement of Acyclovir Permeation Across Human Corneal Epithelial T Cells. Suwannoi P; Chomnawang M; Sarisuta N; Reichl S; Müller-Goymann CC J Ocul Pharmacol Ther; 2017 Dec; 33(10):743-752. PubMed ID: 29111864 [TBL] [Abstract][Full Text] [Related]
11. Span 80/TPGS modified lipid-coated chitosan nanocomplexes of acyclovir as a topical delivery system for viral skin infections. Abd-Elsalam WH; Ibrahim RR Int J Pharm; 2021 Nov; 609():121214. PubMed ID: 34678396 [TBL] [Abstract][Full Text] [Related]
12. Galactose decorated PLGA nanoparticles for hepatic delivery of acyclovir. Gupta S; Agarwal A; Gupta NK; Saraogi G; Agrawal H; Agrawal GP Drug Dev Ind Pharm; 2013 Dec; 39(12):1866-73. PubMed ID: 22397550 [TBL] [Abstract][Full Text] [Related]
13. Development of Oral Lipid Based Nano-formulation of Dapagliflozin: Optimization, in vitro Characterization and ex vivo Intestinal Permeation Study. Zafar A J Oleo Sci; 2020; 69(11):1389-1401. PubMed ID: 33132278 [TBL] [Abstract][Full Text] [Related]
14. Hybrid chitosan-lipid nanoparticles of green tea extract as natural anti-cellulite agent with superior Abosabaa SA; Arafa MG; ElMeshad AN Drug Deliv; 2021 Dec; 28(1):2160-2176. PubMed ID: 34623203 [TBL] [Abstract][Full Text] [Related]
15. Formulation and pharmacokinetic studies of acyclovir controlled-release capsules. Tu J; Wang L; Yang J; Fei H; Li X Drug Dev Ind Pharm; 2001 Aug; 27(7):687-92. PubMed ID: 11694016 [TBL] [Abstract][Full Text] [Related]
16. Formulation of acyclovir-loaded solid lipid nanoparticles: design, optimization, and El-Gizawy SA; El-Maghraby GM; Hedaya AA Pharm Dev Technol; 2019 Dec; 24(10):1287-1298. PubMed ID: 31507232 [TBL] [Abstract][Full Text] [Related]
17. The effect of chitosan on the bioaccessibility and intestinal permeability of acyclovir. Kubbinga M; Augustijns P; García MA; Heinen C; Wortelboer HM; Verwei M; Langguth P Eur J Pharm Biopharm; 2019 Mar; 136():147-155. PubMed ID: 30682491 [TBL] [Abstract][Full Text] [Related]
18. Positively charged polymeric nanoparticle reservoirs of terbinafine hydrochloride: preclinical implications for controlled drug delivery in the aqueous humor of rabbits. Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH AAPS PharmSciTech; 2013 Jun; 14(2):782-93. PubMed ID: 23615773 [TBL] [Abstract][Full Text] [Related]
19. Central Composite Design for Formulation and Optimization of Solid Lipid Nanoparticles to Enhance Oral Bioavailability of Acyclovir. Hassan H; Adam SK; Alias E; Meor Mohd Affandi MMR; Shamsuddin AF; Basir R Molecules; 2021 Sep; 26(18):. PubMed ID: 34576904 [TBL] [Abstract][Full Text] [Related]
20. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. Attia IA; El-Gizawy SA; Fouda MA; Donia AM AAPS PharmSciTech; 2007 Dec; 8(4):E106. PubMed ID: 18181527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]